Bruce is President and CEO at Diapin Therapeutics, serves as a Board Member at Phrixus Pharmaceuticals in Ann Arbor, Michigan, and is a member of the advisory board of Cytometix. Additionally, he is a life sciences mentor-in-residence in Innovation Partnerships and the Technology Transfer Talent Network (T3N).
Prior to Diapin and Phrixus, he was a research fellow at Pfizer and Parke-Davis in the cardiovascular area, where he brought several compounds to the clinical candidate stage, was a member of the Cardiovascular Licensing Team, the Global PPAR team and led the Heart Failure and Hypertension Disease teams. He was an Associate Professor of physiology at the Medical College of Wisconsin, as well as an Established Investigator at the American Heart Association. Dr. Markham received his B.A. degree from Western Michigan University and his PhD degree from Michigan State University. He received his post-doctoral training in molecular genetics and cardiovascular physiology at the University of Arizona.